TriSalus Life Sciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Years Ended | ||
|---|---|---|
| December 31, 2025 | December 31, 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(39,227) | $(30,045) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 626 | 744 |
| Non-cash lease expense | 429 | 264 |
| Change in fair value of SEPA, warrant and revenue base redemption liabilities | 4,086 | 2,107 |
| Change in fair value of contingent earnout liability | 2,743 | (11,231) |
| Paid-in-kind interest | 800 | 604 |
| Stock-based compensation expense | 9,131 | 5,441 |
| Allowance for credit losses | 163 | 187 |
| Loss on disposal of property and equipment | 120 | 23 |
| Amortization of debt issuance costs | 1,049 | 612 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,634) | (1,719) |
| Inventory, net | 971 | (1,503) |
| Prepaid expenses and other assets | 840 | (1,708) |
| Deposits | 5 | 43 |
| Operating lease liabilities | (134) | (278) |
| Trade payables and accrued liabilities | 2,020 | (4,384) |
| Net cash used in operating activities | (18,012) | (40,843) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (918) | (345) |
| Proceeds from disposal of property and equipment | 80 | — |
| Net cash used in investing activities | (838) | (345) |
| Cash flows from financing activities | ||
| Proceeds from the issuance of common stock | 22,000 | 15,104 |
| Common stock issuance costs | (1,549) | — |
| Proceeds from the exercise of stock options for common stock | 510 | 76 |
| Proceeds from the issuance of common stock through employee stock purchase plan | 404 | 433 |
| Debt issuance costs | (520) | (2,593) |
| Proceeds from the issuance of debt | 10,000 | 25,000 |
| Payments on finance lease liabilities | (81) | (84) |
| Net cash provided by financing activities | 30,764 | 37,936 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 11,914 | (3,252) |
| Cash, cash equivalents and restricted cash, beginning of period | 8,875 | 12,127 |
| Cash, cash equivalents and restricted cash, end of period | $20,789 | $8,875 |
| Supplemental disclosures of cash flow information | ||
| Cash paid for interest | 3,697 | 1,750 |
| Cash paid for income taxes | 16 | 18 |
| Supplemental disclosure of noncash items | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | — | 294 |
| Right-of-use assets obtained in exchange for new finance lease liabilities | 66 | — |
| Non-cash capital expenditures included in trade payables | 68 | — |
| Fixed asset purchase through exchange of finance lease right-of-use asset | 85 | — |
| Derecognition of finance lease right-of-use asset | (85) | — |
| Prepaid warrant issuance costs | — | 1,700 |
| Fair value of warrants issued with OrbiMed debt | 366 | 362 |
| Fair value of revenue base redemption liability related to OrbiMed debt | — | 507 |
|---|---|---|
| Transfer of warrant liability to common stock upon exercise of warrant | — | 11,924 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.